Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PA5108 Ocular Implant with Prezia™ technology are being developed to offer a safe and effective, fully biodegradable therapy, which is investigated for the treatment of mild to moderate glaucoma.
Lead Product(s): Latanoprost
Therapeutic Area: Ophthalmology Product Name: PA5108
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2023
Details:
Phase IIa study met primary and secondary efficacy endpoints of at least 20% IOP lowering in its low dose cohort, demonstrating a potential significant benefit of the PA5108 Ocular Implant designed to treat patients with glaucoma by enabling a constant dose of medication.
Lead Product(s): Latanoprost
Therapeutic Area: Ophthalmology Product Name: PA5108
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2022
Details:
The Latanoprost FA SR Ocular Implant is designed to provide a constant daily therapeutic dose of latanoprost free acid (the active ingredient of a commonly prescribed glaucoma eye-drop, Xalatan®) for 6-months.
Lead Product(s): Latanoprost
Therapeutic Area: Ophthalmology Product Name: Xalatan
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020